 |
|
|
Advisory Committee on Immunization Practices |
|
| FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION |
|
ACIP Recommendations: Vaccine index |
|
|
| |
|
|
Recommendations - Anthrax |
|
|
|
Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019
Source: MMWR, December 13, 2019, 68(4);1–14 |
|
| HTML | PDF |
| |
Use of Anthrax Vaccine in
the United States: Recommendations of the Advisory Committee on
Immunization Practices (ACIP), 2009
Source: MMWR, July 23, 2010;
59(rr06):1-36 |
|
| HTML | PDF |
| |
Use of Anthrax Vaccine in Response
to Terrorism
Source: MMWR, November 15, 2002, Vol. 51(45):1024-1026 |
|
| HTML | PDF |
| |
Use of Anthrax
Vaccine in the United States
Source: MMWR December 15, 2000 / Vol. 49 / No. RR-15 |
|
| HTML | PDF |
| |
|
|
|
|
|
Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022
Source: MMWR, September 30, 2022, 71 (2); 1-8 |
| HTML | PDF |
| |
|
Recommendations of the Advisory Committee on Immunization Practices for Use of Cholera Vaccine
Source: MMWR May 12, 2017, 66(18);482–485 |
|
|
HTML | PDF |
| |
|
|
|
|
ACIP interim recommendations for the use of bivalent booster doses of COVID-19 vaccines, US October 2022
Source: MMWR, November 11, 2022, 71(45);1436-1441 |
| HTML | PDF |
| |
|
ACIP Interim Recommendation for Use of the Novavax COVID-19 Vaccine in Adults 18 years and older — US, July 2022
Source: MMWR, August 5, 2022, 71(31);988–992 |
| HTML | PDF |
| |
|
ACIP Interim Recommendations for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
Source: MMWR Early Release June 28, 2022 |
| HTML | PDF |
| |
|
ACIP Recommendation for use of Moderna COVID-19 Vaccine in Adults aged 18 years and older, considerations for extended intervals for primary series doses of mRNA COVID-19 vaccines — US, February 2022
Source: MMWR, March 18, 2022, 71 (11); 416-421 |
| HTML | PDF |
| |
|
ACIP Updated Interim Recommendations for Use of the Janssen (Johnson & Johnson) COVID-19 vaccine, US, December 2021
Source: MMWR, January 21, 2022, 71(3);90-95 |
| HTML | PDF |
| |
|
ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years - US, 2021
Source: MMWR Early Release, November 5, 2021, 70 |
|
|
HTML | PDF |
|
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged 16 Years and older: Recommendations of the Advisory Committee on Immunization Practices — U.S., September 2021
Source: MMWR Early Release, September 21, 2021 |
|
|
HTML | PDF |
|
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from ACIP — US, July 2021
Source: MMWR, August 13, 2021, 70(32);1094-1099 |
|
|
HTML | PDF |
|
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from ACIP — US, June 2021
Source: MMWR Early Release, July 6, 2021 |
|
|
HTML | PDF |
|
ACIP Interim Recommendations for use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 years, US, May 2021
MMWR Early Release, May 14, 2021, 70 |
|
|
HTML | PDF |
|
Updated Recommendation from ACIP for Use of Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia
Syndrome Among Vaccine Recipients — U.S. April 2021
MMWR Early Release, April 27, 2021, 70 |
|
|
HTML | PDF |
| |
ACIP Interim Recommendation for Use of Janssen (Johnson and Johnson) COVID-19 Vaccine - U.S., February 2021
Source: MMWR, March 2, 2021, 70 |
|
|
HTML | PDF |
| |
ACIP Updated Interim Recommendation for Allocation of COVID-19 Vaccine – U.S., December 2020
Source: MMWR, December 22, 2020, 69 |
|
|
HTML | PDF |
| |
ACIP Interim Recommendation for Use of Moderna COVID-19 Vaccine – U.S, December 2020
Source: MMWR, December 20, 2020, 69 |
|
|
HTML | PDF |
| |
ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – U.S., December 2020
Source: MMWR, December 13, 2020, 69 |
|
|
HTML | PDF |
|
| |
ACIP Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine – U.S., 2020
Source: MMWR, December 3, 2020, 69 |
|
|
HTML | PDF |
| |
|
|
|
|
ACIP Recommendations on Dengue Vaccine, US, 2021
Source: MMWR December 17, 2021, 70(6);1–16 |
|
|
HTML | PDF |
| |
|
|
Recommendations - Diphtheria |
|
|
|
Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants
Source: MMWR, February 7, 2020, 69 (5);136-139 |
|
|
HTML | PDF |
| |
Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, January 24, 2020, Vol 69 (3);77-83 |
|
|
HTML | PDF |
| |
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Source: MMWR, April 27, 2018; 67 (2):1-44 |
|
|
HTML | PDF |
| |
Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women - Advisory Committee
on Immunization Practices (ACIP)
Source: MMWR, February 22, 2013;62(07):131-5 |
|
|
HTML | PDF |
|
|
| |
Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine
in Adults Aged 65 Years and Older — Advisory Committee on Immunization Practices (ACIP), 2012
Source: MMWR, June 29, 2012; 61(25):468-70 |
|
|
HTML | PDF |
|
| |
Updated Recommendations for Use of
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis
Vaccine (Tdap) in Pregnant Women and Persons Who Have or
Anticipate Having Close Contact with an Infant Aged <12 Months --
Advisory Committee on Immunization Practices (ACIP), 2011
Source: MMWR, October 21, 2011; 60(41):1424-1426 |
|
|
HTML | PDF |
| |
Updated Recommendations for Use of
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis
(Tdap) Vaccine from the Advisory Committee on Immunization
Practices, 2010
Source:: MMWR, January 14,
2011; 60(01):13-15 |
|
|
HTML | PDF |
| |
Prevention of Pertussis, Tetanus, and
Diphtheria Among Pregnant and Postpartum Women and Their Infants:
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Source: MMWR, May 30, 2008; 57
(04):1-47,51 |
|
|
HTML pt 1 |
HTML pt 2 |
HTML pt 3 |
PDF |
| |
Preventing Tetanus,
Diphtheria, and Pertussis among Adults: Use of Tetanus Toxoid, Reduced
Diphtheria Toxoid and Acellular Pertussis Vaccine
Please
note: If you are using the HTML version of this document, be sure to access
all four HTML links to get the complete content of the document,
which includes 3 important appendices.
Source: MMWR, December 15, 2006;55(RR-17):1-33 |
|
| HTML
pt.1 | HTML
pt.2 | HTML
pt.3 | HTML
pt.4 | PDF
(entire issue) |
| |
Use of Tetanus Toxoid,
Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines Among
Adolescents
Please
note: If you are using the HTML version of this document, be sure to access
all the HTML links to get the complete content of the document,
which includes important appendices.
Source: MMWR, March
24, 2006, Vol. 55(RR03):1-49 |
|
| HTML
pt.1 | HTML
pt.2 | HTML
pt.3 | HTML
pt.4 | HTML
pt.5 | HTML
pt.6 | HTML
pt.7 | PDF
(entire issue) |
| |
Use of Diphtheria
Toxoid-Tetanus Toxoid-Acellular Pertussis Vaccine as a Five-Dose
Series
Source: MMWR November 17, 2000 / Vol. 49 / No. RR-13 |
|
| HTML | PDF |
| |
|
|
|
|
|
Use of Ebola Vaccine: Expansion of ACIP Recommendations to include two additional populations, US, 2021
Source: MMWR, February 25, 2022, 71(8);290–292 |
| HTML | PDF |
| |
|
Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, U.S., 2020
Source: MMWR, January 8, 2021,70(1);1–12 |
|
|
HTML | PDF |
| |
|
|
|
|
|
General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices
Source: CDC website 4/20/17 (this is the original publication date - guidelines are updated by CDC as needed) |
|
|
HTML | PDF |
| |
General Recommendations on
Immunization
Source: MMWR, January 28, 2011; 60(RR02):1-60 |
|
|
HTML | PDF |
| |
General Recommendations
on Immunization
Source: MMWR, December 1, 2006, 55(RR15):1-48 |
|
| HTML | PDF |
|
| |
|
|
Recommendations - Haemophilus influenzae type b (Hib) |
Back to top |
|
|
|
Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants
Source: MMWR, February 7, 2020, 69 (5);136-139 |
|
|
HTML | PDF |
|
| |
Prevention and Control of
Haemophilus influenzae Type b Disease: Recommendations of the
Advisory Committee on Immunization Practices (ACIP)
Recommendations and Reports
Source: MMWR, February 28, 2014; 63(RR01):1-14 |
|
|
HTML | PDF |
| |
Licensure of a Haemophilus
influenzae Type b (Hib) Vaccine (Hiberix) and Updated Recommendations
for Use of Hib Vaccine
Source: MMWR September 18, 2009;
58(36):1008-1009 |
|
| HTML | PDF |
| |
Updated Recommendations for Use of
Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the Booster
Dose at Ages 12 -15 Months
Source: MMWR, June 26, 2009; 58(24):673-4 |
|
| HTML | PDF |
| |
Use of Haemophilus
b Conjugate Vaccines and a Combined DTP and Hib Vaccine
Source: MMWR September 17, 1993 / Vol. 42 / No. RR-13 |
|
| HTML | PDF |
| |
Haemophilus
b Conjugate Vaccines for Prevention of Hib Disease
Source: MMWR January 11, 1991 / Vol. 40 / No. RR-01 |
|
| HTML |
| |
|
|
Recommendations - Hepatitis A |
|
|
|
Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, July 3, 2020, Vol 69 (5);1-38 |
|
|
HTML | PDF |
| |
Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness
Source: MMWR, February 15, 2019; 68(6);153–156 |
|
|
HTML | PDF |
| |
Update: Recommendations of the
Advisory Committee on Immunization Practices for Use of Hepatitis
A Vaccine for Postexposure Prophylaxis and for Preexposure
Prophylaxis for International Travel
Source: MMWR, November 2, 2018; 67(43);1216–1220 |
|
|
HTML | PDF |
| |
Sexually Transmitted Diseases
Treatment Guidelines, 2010
(Not an ACIP statement but an
important document. Includes information on hepatitis A, hepatitis
B, and human papillomavirus [HPV] vaccination.)
Source: MMWR, December 17, 2010; 59(RR12):1-110 |
|
|
HTML | PDF |
| |
Updated Recommendations from
the Advisory Committee on Immunization Practices (ACIP) for Use of
Hepatitis A Vaccine in Close Contacts of Newly Arriving International
Adoptees
Source: MMWR, September 18, 2009;
58(36):1006-1007 |
|
| HTML | PDF |
| |
Update: Prevention
of Hepatitis A after Exposure to Hepatitis A Virus and in
International Travelers
Source: MMWR, October 19, 2007; 56(41):1080-1084 |
|
| HTML | PDF |
| |
Prevention of Hepatitis
A Through Active or Passive Immunization
Source: MMWR, May 19, 2006, Vol. 55(RR07):1-23 |
|
| HTML | PDF |
| |
Correctional Settings: Prevention and
Control of Infections with Hepatitis Viruses in Correctional Settings
(not an ACIP statement but an important document)
Source: MMWR, January 24, 2003, Vol. 52(RR-1):1-44 |
|
| PDF |
| |
|
|
|
|
Universal Hepatitis B Vaccination in Adults Aged 19–59 Years, updated ACIP recommendations
Source: MMWR, April 1, 2022, 71(13);477–483 |
| HTML | PDF |
| |
|
Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants
Source: MMWR, February 7, 2020, 69 (5);136-139 |
|
|
HTML | PDF |
|
| |
Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant
Source: MMWR, April 20, 2018; 67 (15): 455-458 |
|
|
HTML | PDF |
| |
Prevention of Hepatitis B
Virus Infection in the United States: Recommendations of the
Advisory Committee on Immunization Practices
Source: MMWR, January 12, 2018; 67 (1); 1–31 |
|
|
HTML | PDF |
| |
Update: Shortened Interval
for Postvaccination Serologic Testing of Infants Born to
Hepatitis B-Infected Mothers
Source: MMWR, October 9,
2015; 64(39):1118-20
(Not an ACIP statement but an important document from CDC.) |
|
|
HTML | PDF |
| |
CDC Guidance for Evaluating
Health-Care Personnel for Hepatitis B Virus Protection and
for Administering Postexposure Management – Recommendations
and Reports
Source: MMWR, December 20,
2013; 62(rr10);1-19
(Not an ACIP statement but an important document from CDC.) |
|
|
HTML | PDF |
| |
Updated CDC Recommendations
for the Management of Hepatitis B Virus–Infected Health-Care
Providers and Students
(Not an ACIP statement
but an important document from CDC.)
Source: MMWR, July 6,
2012; 61(RR03):1-12 |
|
|
HTML | PDF |
| |
Use of Hepatitis B Vaccination for Adults with Diabetes Mellitus: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Source: MMWR, December 23, 2011; 60(50):1709-11 |
|
| HTML | PDF |
| |
Sexually Transmitted Diseases
Treatment Guidelines, 2010
(Not an ACIP statement but an
important document. Includes information on hepatitis A, hepatitis
B, and human papillomavirus [HPV] vaccination.)
Source: MMWR, December 17, 2010; 59(RR12):1-110 |
|
|
HTML | PDF |
| |
Recommendations
for Identification and Public Health Management of Persons with Chronic
Hepatitis B Virus Infection
Source: MMWR, September 19, 2008; 57(RR--8):1-20
(Not an ACIP statement, but an important new recommendation from CDC) |
|
| HTML | PDF |
| |
A Comprehensive Immunization
Strategy to Eliminate Transmission of Hepatitis B Virus Infection
in the United States. Part II: Immunization of Adults
Please note: If you are using
the HTML version of this document, be sure to access all four
HTML links to get the complete content of the document, which
includes 3 important appendices.
Source: MMWR, December 8, 2006;55(RR-16):1-25R |
|
| HTML
pt.1 | HTML
pt.2 | HTML
pt.3 | HTML
pt.4 | PDF
(entire issue) |
| |
A Comprehensive Immunization
Strategy to Eliminate Transmission of Hepatitis B Virus Infection
in the United States. Part 1: Immunization of Infants, Children
and Adolescents.
Please note: If you are using the HTML version of this document, be sure
to access all four HTML links to get the complete content of the document,
which includes 3 important appendices.
Source: MMWR, December
23, 2005, Vol. 54(RR-16):1-39 |
|
| HTML
pt.1 | HTML
pt.2 | HTML
pt.3 | HTML
pt.4 | PDF
(entire issue) |
| |
Correctional Settings: Prevention and
Control of Infections with Hepatitis Viruses in Correctional Settings
(not an ACIP statement but an important document)
Source: MMWR, January 24, 2003, Vol. 52(RR-1):1-44 |
|
| PDF |
| |
Management of
Occupational Exposures to HBV, HCV, and HIV and Recommendations
for Postexposure Prophylaxis
(not an ACIP statement but an important update document)
Source: MMWR June 29, 2001 / Vol. 50 / No. RR-11 |
|
| HTML | PDF |
| |
Recommendations
for Preventing Transmission of Human Immunodeficiency Virus and
Hepatitis B Virus to Patients During Exposure-Prone Invasive Procedures
(not an ACIP statement but an important document)
Source: MMWR, July 12, 1991 / Vol. 40 / No. RR08 |
|
| HTML |
| |
Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination: Recommendations of the
Immunization Practices Advisory Committee (ACIP)
Source: MMWR November 22, 1991 / Vol 40/No. RR-13 |
|
| HTML |
| |
Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination: Recommendations of the ACIP
APPENDIX A: Postexposure Prophylaxis for Hepatitis B
MMWR November 22, 1991 / Vol 40/No. RR-13 |
|
| HTML |
| |
Protection Against Viral Hepatitis Recommendations of the Immunization Practices Advisory Committee (ACIP)
MMWR February 9, 1990 / Vol 39 / No. RR-2 |
|
| HTML |
| |
|
|
Recommendations - Human papillomavirus (HPV) |
Back to top |
|
|
|
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR August 16, 2019; 68(32): 698–702 |
|
|
HTML | PDF |
| |
Use of a 2-Dose Schedule for Human Papillomavirus Vaccination: Updated Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, December 16, 2016; 65(49);1405-8 |
|
|
HTML | PDF |
| |
Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory
Committee on Immunization Practices
Source: MMWR, March 27, 2015; 64(11):300-304 |
|
|
HTML | PDF |
| |
Human Papillomavirus Vaccination:
Recommendations of the Advisory Committee on Immunization
Practices (ACIP)
Source: MMWR, August 29, 2014; 63(RR-5):1-30 |
|
|
HTML | PDF |
| |
Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males — Advisory Committee on Immunization Practices (ACIP), 2011
Source: MMWR, December 23, 2011; 60(50):1705-8 |
|
| HTML | PDF |
| |
Sexually Transmitted Diseases
Treatment Guidelines, 2010
(Not an ACIP statement but an
important document. Includes information on hepatitis A, hepatitis
B, and human papillomavirus [HPV] vaccination.)
Source: MMWR, December 17, 2010; 59(RR12):1-110 |
|
|
HTML | PDF |
| |
FDA Licensure of Bivalent
Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and
Updated HPV Vaccination Recommendations from the Advisory Committee on
Immunization Practices (ACIP)
Source: MMWR, May 28, 2010;
59(20):626-629 |
|
| HTML | PDF |
| |
FDA Licensure of
Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in
Males and Guidance from the Advisory Committee on Immunization
Practices (ACIP) Weekly
Source: MMWR, May 28, 2010;
59(20):630-632 |
|
| HTML | PDF |
| |
Quadrivalent
Human Papillomavirus Vaccine
Source: MMWR, March 23, 2007; 56(RR02):1-24 |
|
| HTML | PDF |
| |
|
|
|
|
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2023
Source: MMWR, February 10, 2023 / 72(6);141–144 |
| HTML | PDF |
| |
|
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2023
Source: MMWR, February 10, 2023 / 72(6);137–140 |
| HTML | PDF |
| |
|
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2022
Source: MMWR, February 18, 2022, 71(7); 229-233 |
| HTML | PDF |
| |
|
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2022
Source: MMWR, February 18, 2022, 71(7); 234-237 |
| HTML | PDF |
| |
|
| >> past years' immunization schedules |
| |
|
|
|
|
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season
Source: MMWR, August 26, 2022, 71(1); 1-28 |
| HTML | PDF |
| |
|
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States,
2021–22 Influenza Season
Source: MMWR, August 27, 2021, 70(5); 1–28 |
|
|
HTML | PDF |
|
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season
Source: MMWR, August 21, 2020, 69 (8); 1–24 |
|
|
HTML | PDF |
| |
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season
Source: MMWR, August 23, 2019, 68(3); 1–21 |
|
|
HTML | PDF |
| |
Prevention and Control of
Seasonal Influenza with Vaccines: Recommendations of the
Advisory Committee on Immunization Practices - United States,
2018–19 Influenza Season
Source: MMWR, August 24, 2018,
67(3); 1-20 |
|
|
HTML | PDF |
| |
Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) — United States, 2018–19 Influenza Season
Source: MMWR, June 8, 2018; 67 (22); 643–645 |
|
|
HTML | PDF |
| |
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18
Influenza Season
Source: MMWR, August 25, 2017, 66(2); 1–20 |
|
|
HTML | PDF |
|
| |
Prevention and Control of Seasonal
Influenza with Vaccines: Recommendations of the Advisory Committee
on Immunization Practices, United States, 2016–17 Influenza Season
Source: MMWR, August 26, 2016, Vol. 65(5):1-54 |
|
|
HTML | PDF |
| |
Prevention and Control of
Influenza with Vaccines: Recommendations of the Advisory
Committee on Immunization Practices, United States, 2015–16
Influenza Season
Source: MMWR, August 7, 2015; 64(30):818-825 |
|
|
HTML | PDF |
| |
Prevention and Control of
Seasonal Influenza with Vaccines: Recommendations of the
Advisory Committee on Immunization Practices — United States,
2014–2015
Source: MMWR, August 15, 2014; 63(327):691–697 |
|
|
HTML | PDF |
| |
Prevention and Control of
Seasonal Influenza with Vaccines: Recommendations of the
Advisory Committee on Immunization Practices — United States,
2013–2014
Source: MMWR, September 20, 2013; 62(RR–7):1-48 |
|
|
HTML | PDF |
| |
Prevention and Control of Influenza with Vaccines: Interim Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013 Weekly
Source: MMWR, May 10, 2013; 62(18):356 |
|
|
HTML | PDF |
| |
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2012–13
Influenza Season
Source: MMWR, August 18, 2012;61(32);613-8 |
|
|
HTML | PDF |
| |
Antiviral Agents for the
Treatment and Chemoprophylaxis of Influenza
Source: MMWR, January 21, 2011; 60(RR01):1-24 |
|
|
HTML | PDF |
| |
Licensure of a High-Dose
Inactivated Influenza Vaccine for Persons Aged >=65 Years (Fluzone
High-Dose) and Guidance for Use--United States, 2010
Source: MMWR, April 30, 2010; 59(16):485-486 |
|
| HTML | PDF |
| |
Expansion of Use of Live Attenuated
Influenza Vaccine (FluMist) to Children Aged 2-4 Years and Other
FluMist Changes for the 2007--08 Influenza Season
Source: MMWR, November
23, 2007; 56(46):1217-1219 |
|
| HTML | PDF |
| |
Influenza Vaccination
of Health-Care Personnel
Source: MMWR, February 24, 2006, Vol. 55(RR02):1-16 |
|
| HTML | PDF |
| |
Using Live, Attenuated Influenza Vaccine
for Prevention and Control of Influenza
Source: MMWR, September 26, 2003, Vol. 52/No. RR-13 (file size 402 KB) |
|
| HTML | PDF |
| |
|
|
Recommendations - Japanese Encephalitis |
|
|
|
Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, July 19, 2019, 68(2); 1-33 |
|
|
HTML | PDF |
|
Use of Japanese Encephalitis
Vaccine in Children: Recommendations of the Advisory
Committee on Immunization Practices, 2013
Source: MMWR, November 15, 2013; 62(45):898-900 |
|
|
HTML | PDF |
Recommendations for Use of a
Booster Dose of Inactivated Vero Cell Culture-Derived Japanese
Encephalitis Vaccine -- Advisory Committee on Immunization
Practices, 2011
Source: MMWR, May 27, 2011;
60(20):661-3 |
|
|
HTML | PDF |
| |
Update on Japanese Encephalitis
Vaccine for Children
Source: MMWR, May 27, 2011; 60(20):664-5 |
|
HTML | PDF |
|
| |
Japanese Encephalitis Vaccines
Source: MMWR, March 12, 2010;
59(01):1-27 |
|
| HTML | PDF |
| |
Inactivated Japanese Encephalitis Virus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Source: MMWR January 8, 1993;42(RR 01):1-15 |
|
HTML | PDF |
|
|
|
|
|
|
Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Source: MMWR, November 18, 2022, 71 (46); 1465-1470 |
| HTML | PDF |
| |
|
Interim Infection Prevention and Control Recommendations for Measles in Healthcare Settings
Source: CDC Infection Control Guideline Library
Updated July 2019
(Not an ACIP statement but an important document from CDC.) |
|
|
HTML | PDF |
| |
Prevention of Measles, Rubella,
Congenital Rubella Syndrome, and Mumps, 2013 -- Summary
Recommendations of the Advisory Committee on Immunization
Practices (ACIP)
Source: MMWR, June 14, 2013; 62(RR04):1-34 |
|
|
HTML | PDF |
| |
Use of Combination Measles,
Mumps, Rubella, and Varicella Vaccine--Recommendations of the Advisory
Committee on Immunization Practices
Source: MMWR, May 7, 2010; 59(RR--3):1 - 16 |
|
| HTML | PDF |
| |
Measles, Mumps,
and Rubella--Vaccine Use and Strategies
Source: MMWR May 22, 1998 / Vol. 47 / No. RR-8 |
|
| HTML | PDF |
| |
|
|
|
|
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, September 25, 2020, Volume 69(9); 1–41 |
|
|
HTML | PDF |
| |
Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons – Advisory Committee on Immunization Practices (ACIP), 2016
Source: MMWR, November 4, 2016, Vol. 65(43);1189–1194 |
|
|
HTML | PDF |
| |
Use of MenACWY-CRM Vaccine in
Children Aged 2 Through 23 Months at Increased Risk for
Meningococcal Disease
Source: MMWR, June 20, 2014; 63(24):527-530 |
|
|
HTML | PDF |
| |
Prevention and Control of
Meningococcal Disease: Recommendations of the Advisory Committee
on Immunization Practices (ACIP)
Source: MMWR, March 22,
2013; 62(RR02):1-22 |
|
|
HTML | PDF |
| |
Infant Meningococcal Vaccination:
Advisory Committee on Immunization Practices (ACIP)
Recommendations and Rationale
Source: MMWR, January 25,
2013; 62(3):52-4 |
|
|
HTML | PDF |
| |
Recommendation of the Advisory
Committee on Immunization Practices (ACIP) for Use of Quadrivalent
Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9
Through 23 Months at Increased Risk for Invasive Meningococcal
Disease
Source: MMWR, October 14, 2011; 60(40):1391-2 |
|
|
HTML | PDF |
| |
Licensure of a Meningococcal
Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated
Booster Dose Guidance for Adolescents and Other Persons at
Increased Risk for Meningococcal Disease — Advisory Committee on
Immunization Practices (ACIP), 2011
Source: MMWR, August 5, 2011;
60(30):1018-1019 |
|
|
HTML | PDF |
| |
Updated Recommendations
for Use of Meningococcal Conjugate Vaccines--Advisory Committee on
Immunization Practices (ACIP), 2010
Source: MMWR, January 28, 2011; 60(03):72-76 |
|
|
HTML | PDF |
| |
Licensure of a Meningococcal
Conjugate Vaccine (Menveo) and Guidance for Use--Advisory Committee on
Immunization Practices (ACIP), 2010
Source: MMWR, March 12, 2010;
59(09):273 |
|
| HTML | PDF |
| |
Updated Recommendation from
the Advisory Committee on Immunization Practices (ACIP) for
Revaccination of Persons at Prolonged Increased Risk for Meningococcal
Disease
Source: MMWR, September 25, 2009; 58(37):1042-1043 |
|
| HTML | PDF |
| |
Recommendation
from the Advisory Committee on Immunization Practices (ACIP) for
Use of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in Children
Aged 2--10 Years at Increased Risk for Invasive Meningococcal Disease
Source: MMWR, December 7, 2007; 56(48):1265-1266 |
|
| HTML | PDF |
| |
Revised Recommendations
of the ACIP to Vaccinate All Persons Aged 11--18 Years with Meningococcal
Conjugate Vaccine
Source: MMWR, August 10, 2007; 56(31):794-795 |
|
| HTML | PDF |
| |
Prevention and Control of Meningococcal
Disease
Source: MMWR, May 27, 2005, Vol. 54(RR07):1-21 |
|
| HTML | PDF |
| |
Prevention and Control of Meningococcal Disease
Source: MMWR June 30, 2000 / Vol. 49 / No. RR-07 |
|
| HTML | PDF |
| |
Meningococcal Disease and College Students
Source: MMWR June 30, 2000 / Vol. 49 / No. RR-07 |
|
| HTML | PDF |
|
|
|
Recommendations - Meningococcal B |
|
|
|
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, September 25, 2020, Volume 69(9); 1–41 |
|
|
HTML | PDF |
| |
Updated Recommendations for Use of MenB-FHbp Serogroup B (Trumenba) Meningococcal Vaccine
Source: MMWR, May 19, 2017; 66(19); 509-513 |
|
|
HTML | PDF |
| |
Use of Serogroup B Meningococcal
Vaccines in Adolescents and Young Adults: Recommendations of the
Advisory Committee on Immunization Practices (ACIP), 2015
Source: MMWR, October 23, 2015; 64(41)1171–1176 |
|
|
HTML | PDF |
| |
Use of Serogroup B Meningococcal
Vaccines in Persons Aged >10 Years at Increased Risk for
Serogroup B Meningococcal Disease: Recommendations of the Advisory
Committee on Immunization Practices, 2015
Source: MMWR, June 12, 2015; 64(22);608-612 |
|
|
HTML | PDF |
| |
| |
|
|
|
|
Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Source: MMWR, November 18, 2022, 71 (46); 1465-1470 |
| HTML | PDF |
| |
|
Recommendations of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for
Mumps During an Outbreak
Source: MMWR, January 12, 2018; 67(1); 33–37 |
|
|
HTML | PDF |
| |
Prevention of Measles, Rubella,
Congenital Rubella Syndrome, and Mumps, 2013 -- Summary
Recommendations of the Advisory Committee on Immunization
Practices (ACIP)
Source: MMWR, June 14, 2013; 62(RR04):1-34 |
|
|
HTML | PDF |
| |
Use of Combination Measles,
Mumps, Rubella, and Varicella Vaccine--Recommendations of the Advisory
Committee on Immunization Practices
Source: MMWR, May 7, 2010; 59(RR--3):1 - 16 |
|
| HTML | PDF |
| |
Control and Elimination
of Mumps
Source: MMWR, June 9, 2006, Vol. 55(22):629-630 |
|
| HTML | PDF |
| |
Measles, Mumps,
and Rubella--Vaccine Use and Strategies
Source: MMWR May 22, 1998 / Vol. 47 / No. RR-8 |
|
| HTML | PDF |
| |
|
|
|
|
Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants
Source: MMWR, February 7, 2020, 69 (5);136-139 |
|
|
HTML | PDF |
| |
Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, January 24, 2020, Vol 69 (3);77-83 |
|
|
HTML | PDF |
| |
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Source: MMWR, April 27, 2018; 67 (2):1-44 |
|
|
HTML | PDF |
| |
Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women - Advisory Committee
on Immunization Practices (ACIP)
Source: MMWR, February 22, 2013;62(07):131-5 |
|
|
HTML | PDF |
|
|
| |
Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine
in Adults Aged 65 Years and Older — Advisory Committee on Immunization Practices (ACIP), 2012
Source: MMWR, June 29, 2012; 61(25):468-70 |
|
|
HTML | PDF |
|
| |
Updated Recommendations for Use of
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis
Vaccine (Tdap) in Pregnant Women and Persons Who Have or
Anticipate Having Close Contact with an Infant Aged <12 Months --
Advisory Committee on Immunization Practices (ACIP), 2011
Source: MMWR, October 21, 2011; 60(41):1424-1426 |
|
|
HTML | PDF |
| |
Updated Recommendations for Use of
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis
(Tdap) Vaccine from the Advisory Committee on Immunization
Practices, 2010
Source:: MMWR, January 14,
2011; 60(01):13-15 |
|
|
HTML | PDF |
| |
Prevention of Pertussis, Tetanus, and
Diphtheria Among Pregnant and Postpartum Women and Their Infants:
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Source: MMWR, May 30, 2008; 57
(04):1-47,51 |
|
|
HTML pt 1 |
HTML pt 2 |
HTML pt 3 |
PDF |
| |
Preventing Tetanus,
Diphtheria, and Pertussis among Adults: Use of Tetanus Toxoid, Reduced
Diphtheria Toxoid and Acellular Pertussis Vaccine
Please note: If you are using the HTML version of this
document, be sure to access all four HTML links to get the complete content
of the document,
which includes 3 important appendices.
Source: MMWR, December
15, 2006;55(RR-17):1-33 |
|
| HTML
pt.1 | HTML
pt.2 | HTML
pt.3 | HTML
pt.4 | PDF
(entire issue) |
| |
Use of Tetanus Toxoid,
Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines Among
Adolescents
Please note: If you are using the HTML version of this document, be sure
to access all the HTML links to get the complete content of the document,
which includes important appendices.
Source:
MMWR, March 24, 2006, Vol. 55(RR03):1-49 |
|
| HTML
pt.1 | HTML
pt.2 | HTML
pt.3 | HTML
pt.4 | HTML
pt.5 | HTML
pt.6 | HTML
pt.7 | PDF
(entire issue) |
| |
CDC
Treatment Guidelines: Recommended Antimicrobial Agents for the Treatment
and Postexposure Prophylaxis of Pertussis
(not an ACIP statement but a recommendation from NIP, CDC)
Source: MMWR, December 9, 2005, Vol. 54(RR14):1-16 |
|
| HTML | PDF |
| |
Use of Diphtheria
Toxoid-Tetanus Toxoid-Acellular Pertussis Vaccine as a Five-Dose
Series
Source: MMWR November 17, 2000 / Vol. 49 / No. RR-13 |
|
| HTML | PDF |
| |
Use of Acellular
Pertussis Vaccines
Source: MMWR March 28, 1997 / Vol. 46 / No. RR-7 |
|
| HTML | PDF |
| |
|
|
|
|
Prevention of
Plague
Source: MMWR December 13, 1996 / Vol. 45 / No. RR-14 |
|
| PDF |
| |
|
|
|
|
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices-US, 2022
Source: MMWR, September 16, 2022, 71(37);1174–1181 |
| HTML | PDF |
| |
|
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, January 28, 2022, 71 (4); 109-117 |
| HTML | PDF |
| |
|
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged 65 Years and older: Updated Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, November 22, 2019; 68(46):1069–1075 |
|
|
HTML | PDF |
| |
Intervals Between PCV13 and PPSV23
Vaccines: Recommendations of the Advisory Committee on
Immunization Practices (ACIP)
Source: MMWR, September 4, 2015; 64(34):944-947 |
|
|
HTML | PDF |
| |
Use of 13-Valent
Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal
Polysaccharide Vaccine Among Adults Aged >65 Years:
Recommendations of the
Advisory Committee on Immunization Practices (ACIP)
Source: MMWR, September 19, 2014; 63(37):822-825 |
|
|
HTML | PDF |
| |
Use of 13-Valent Pneumococcal
Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide
Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the
Advisory Committee on Immunization Practices (ACIP)
Source: MMWR, June 28,
2013; 62(25):521-524 |
|
|
HTML | PDF |
| |
Use of 13-Valent Pneumococcal
Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide
Vaccine for Adults with Immunocompromising Conditions:
Recommendations of the Advisory Committee on Immunization
Practices (ACIP)
Source: MMWR, October 12,
2012; 61(40):816-9 |
|
|
HTML | PDF |
| |
Licensure of 13-Valent Pneumococcal Conjugate Vaccine for Adults Aged 50 Years and Older
Source: MMWR, June 1, 2012; 61(21):394-5 |
|
|
HTML | PDF |
| |
Prevention of
Pneumococcal Disease Among Infants and Children--Use of 13-Valent
Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal
Polysaccharide Vaccine
Source: MMWR, December 10,
2010; 59(RR11):1-18 |
|
|
HTML | PDF |
| |
Updated ACIP
Recommendations: Prevention of Invasive Pneumococcal Disease Among
Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine
(PPSV23)
Source: MMWR, September 3, 2010; 59(34):1102-6 |
|
| HTML | PDF |
| |
Licensure of a 13-Valent
Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use
Among Children --- Advisory Committee on Immunization Practices
(ACIP), 2010
Source: MMWR, March 12, 2010;
59(09):258-261 |
|
| HTML | PDF |
| |
Updated Recommendation from the
Advisory Committee on Immunization Practices (ACIP) for Use of 7-Valent
Pneumococcal Conjugate Vaccine (PCV7) in Children Aged 24--59 Months Who
Are Not Completely Vaccinated
Source: MMWR, April 4, 2008; 57(13):343-344 |
|
| HTML | PDF |
| |
Pneumococcal Vaccination for Cochlear
Implant Candidates and Recipients
Source: MMWR, Early Release, July 31, 2003, Vol. 52;1-2 |
|
| HTML | PDF |
| |
Preventing
Pneumococcal Disease Among Infants and Young Children
Source: MMWR
October 6, 2000 / Vol. 49 / No. RR-09 |
|
| HTML | PDF |
| |
Prevention of
Pneumococcal Disease
Source: MMWR April 04, 1997 / Vol. 46 / No. RR-08 |
|
| HTML | PDF |
| |
|
|
|
|
Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants
Source: MMWR, February 7, 2020, 69 (5);136-139 |
|
|
HTML | PDF |
|
| |
Guidance for Assessment of
Poliovirus Vaccination Status and Vaccination of Children Who Have
Received Poliovirus Vaccine Outside the United States
Source: MMWR, January 13, 2017; 66(01); 23–25
(Not an ACIP statement but an important document from CDC.) |
|
|
HTML | PDF |
|
Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine Poliovirus Vaccination
Source: MMWR, August 7, 2009; 58(30):829-30 |
|
|
HTML | PDF |
| |
Poliomyelitis
Prevention in the United States
Source: MMWR May 19, 2000 / Vol. 49 / No. RR-05 |
|
| HTML | PDF |
| |
|
|
|
|
Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices — US, 2022
Source: MMWR, May 6, 2022, 71(18);619–627 |
| HTML | PDF |
| |
|
Use of a Reduced (4-Dose)
Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies
Source: MMWR, March 19, 2010;
59(02):1-9 |
|
| HTML | PDF |
| |
Human Rabies Prevention--United
States, 2008: Recommendations of the Advisory Committee on Immunization
Practices
Source: MMWR, May 23, 2008; 57(RR03):1-26,28 |
|
|
HTML pt 1 |
HTML pt 2 | PDF |
| |
|
|
Recommendations - Rotavirus |
|
|
|
History of Intussusception as a Contraindication for Rotavirus Vaccination
Source: Source: MMWR, October 21, 2011;60(41):1427-1427 |
|
|
HTML | PDF |
| |
Severe Combined Immunodeficiency as a Contraindication for Administration of Rotavirus Vaccine
Source: Source: MMWR June 11, 2010;59(22):687-688 |
|
|
HTML | PDF |
| |
Prevention of Rotavirus Gastroenteritis
Among Infants and Children: Recommendations of the Advisory Committee on
Immunization Practices
Source: MMWR, February 6, 2009, Vol. 58
(RR-2) |
|
| HTML | PDF |
| |
|
|
Recommendations - Rubella |
|
|
|
Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Source: MMWR, November 18, 2022, 71 (46); 1465-1470 |
| HTML | PDF |
| |
|
Prevention of Measles, Rubella,
Congenital Rubella Syndrome, and Mumps, 2013 -- Summary
Recommendations of the Advisory Committee on Immunization
Practices (ACIP)
Source: MMWR, June 14, 2013; 62(RR04):1-34 |
|
|
HTML | PDF |
| |
Use of Combination Measles,
Mumps, Rubella, and Varicella Vaccine--Recommendations of the Advisory
Committee on Immunization Practices
Source: MMWR, May 7, 2010; 59(RR--3):1 - 16 |
|
| HTML | PDF |
| |
CDC Guidelines:
Evaluation and Management of Suspected Outbreaks, Rubella in Pregnant
Women, and Surveillance for Congenital Rubella Syndrome
(not an ACIP statement but an important update document)
Source: MMWR July 13, 2001 / Vol. 50 / No. RR-12 |
|
| HTML | PDF |
| |
Measles, Mumps,
and Rubella--Vaccine Use and Strategies
Source: MMWR May 22, 1998 / Vol. 47 / No. RR-8 |
|
| HTML | PDF |
| |
|
|
|
|
Use of Vaccinia Virus
Smallpox Vaccine in Laboratory and Health Care Personnel at
Risk for Occupational Exposure to Orthopoxviruses—Recommendations
of the Advisory Committee on Immunization Practices (ACIP),
2015
Source: MMWR, March 18, 2016, Vol. 65(10):257-262 |
|
|
HTML | PDF |
| |
Recommendations for Using Smallpox
Vaccine in a Pre-Event Vaccination Program
Source: MMWR, Recommendations and Reports, April 4, 2003, Vol. 52(RR-7) |
|
| HTML | PDF |
| |
Vaccinia (Smallpox)
Vaccine
Source: MMWR June 22, 2001 / Vol. 50 / No. RR-10 |
|
| HTML | PDF |
| |
|
|
Recommendations - Smallpox and Monkeypox |
|
|
|
Use of Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — US, 2022
Source: MMWR, May 27, 2022, Vol 71 |
| HTML | PDF |
| |
|
|
| |
|
|
Recommendations - Tetanus |
|
|
|
Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants
Source: MMWR, February 7, 2020, 69 (5);136-139 |
|
|
HTML | PDF |
| |
Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, January 24, 2020, Vol 69 (3);77-83 |
|
|
HTML | PDF |
| |
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Source: MMWR, April 27, 2018; 67 (2):1-44 |
|
|
HTML | PDF |
| |
Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women - Advisory Committee
on Immunization Practices (ACIP)
Source: MMWR, February 22, 2013;62(07):131-5 |
|
|
HTML | PDF |
|
|
| |
Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine
in Adults Aged 65 Years and Older — Advisory Committee on Immunization Practices (ACIP), 2012
Source: MMWR, June 29, 2012; 61(25):468-70 |
|
|
HTML | PDF |
|
| |
Updated Recommendations for Use of
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis
Vaccine (Tdap) in Pregnant Women and Persons Who Have or
Anticipate Having Close Contact with an Infant Aged <12 Months --
Advisory Committee on Immunization Practices (ACIP), 2011
Source: MMWR, October 21, 2011; 60(41):1424-1426 |
|
|
HTML | PDF |
| |
Updated Recommendations for Use of
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis
(Tdap) Vaccine from the Advisory Committee on Immunization
Practices, 2010
Source: MMWR, January 14, 2011;
60(01):13-15 |
|
|
HTML | PDF |
| |
Prevention of Pertussis, Tetanus, and
Diphtheria Among Pregnant and Postpartum Women and Their Infants:
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Source: MMWR, May 30, 2008; 57
(04):1-47,51 |
|
|
HTML pt 1 |
HTML pt 2 |
HTML pt 3 |
PDF |
| |
Preventing Tetanus,
Diphtheria, and Pertussis among Adults: Use of Tetanus Toxoid, Reduced
Diphtheria Toxoid and Acellular Pertussis Vaccine
Please note: If you are using the HTML version of this
document, be sure to access all four HTML links to get the complete content
of the document,
which includes 3 important appendices.
Source: MMWR, December 15,
2006;55(RR-17):1-33 |
|
| HTML
pt.1 | HTML
pt.2 | HTML
pt.3 | HTML
pt.4 | PDF
(entire issue) |
| |
Use of Tetanus Toxoid,
Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines Among
Adolescents
Please note: If you are using the HTML version
of this document, be sure to access all the HTML links to get the
complete content of the document,
which includes important appendices.
Source:
MMWR, March 24, 2006, Vol. 55(RR03):1-49 |
|
| HTML
pt.1 | HTML
pt.2 | HTML
pt.3 | HTML
pt.4 | HTML
pt.5 | HTML
pt.6 | HTML
pt.7 | PDF
(entire issue) |
| |
Use of Diphtheria
Toxoid-Tetanus Toxoid-Acellular Pertussis Vaccine as a Five-Dose
Series
Source: MMWR November 17, 2000 / Vol. 49 / No. RR-13 |
|
| HTML | PDF |
| |
|
|
Recommendations - Typhoid |
|
|
|
Updated Recommendations for the Use of Typhoid Vaccine — Advisory Committee on Immunization Practices, United States, 2015
Source: MMWR March 27, 2015;64(11):305–308 |
|
|
HTML | PDF |
| |
Typhoid Immunization
Source: MMWR December 9, 1994/ Vol. 43/ No. RR-14 |
|
| HTML | PDF |
| |
|
|
Recommendations - Varicella (chickenpox) |
|
|
|
Updated Recommendations for Use of
VariZIG -- United States, 2013
Source: MMWR, July 19, 2013; 62(28):574-6 |
|
|
HTML | PDF |
| |
Use of Combination Measles, Mumps, Rubella, and Varicella Vaccine--Recommendations of the Advisory Committee on Immunization Practices
Source: MMWR, May 7, 2010; 59(RR--3):1-16 |
|
|
HTML | PDF |
| |
Prevention of Varicella
Source: MMWR, June 22, 2007; 56(RR-4):1-40 |
|
| HTML | PDF |
| |
Investigational Product
(VariZIG™) for Postexposure Prophylaxis of Varicella
Source: MMWR, February 24, 2006, Vol. 55:1-2 |
|
| HTML | PDF |
| |
|
|
|
|
Yellow Fever Vaccine Booster
Doses: Recommendations of the Advisory Committee on Immunization
Practices, 2015
Source: MMWR, June 19, 2015; 64(23);647-650 |
|
|
HTML | PDF |
| |
Yellow Fever Vaccine:
Recommendations of the Advisory Committee on Immunization Practices
(ACIP)
Source: MMWR, July 30, 2010;
59(RR07):1-27 |
|
| HTML | PDF |
| |
Yellow Fever Vaccine
Source: MMWR, November 8, 2002, Vol. 51/RR17 |
|
| HTML | PDF |
| |
|
|
Recommendations - Zoster (shingles) |
|
|
|
ACIP Recommendations for Use of Recombinant Zoster Vaccine (RZV, Shingrix, GSK) in Immunocompromised Adults aged 19 years and older, US, 2022
Source: MMWR, January 21, 2022, 71(3);80-84 |
| HTML | PDF |
| |
|
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
Source: MMWR, January 26, 2018; 67(3); 103–108 |
|
|
HTML | PDF |
| |
Update on Recommendations for Use
of Herpes Zoster Vaccine
Source: MMWR, August 22, 2014; 63(33):729-731 |
|
|
HTML | PDF |
| |
Prevention of Herpes Zoster:
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Source: MMWR, June 6, 2008; 57(05):1-30 |
|
| HTML | PDF |
|
| This page was updated on February 10, 2023. |
|
| This page was reviewed on February 10, 2023. |
|
|
|
|
ACIP Recommendations
Vaccine Information Statements 
IAC Home
